Assessing the emetic potential of PDE4 inhibitors in rats

@article{Robichaud2002AssessingTE,
  title={Assessing the emetic potential of PDE4 inhibitors in rats},
  author={Annette Robichaud and Chantal Savoie and Panagiota B Stamatiou and N Lachance and Paul Jolicoeur and R Rasori and C. C. Chan},
  journal={British Journal of Pharmacology},
  year={2002},
  volume={135}
}
Type 4 phosphodiesterase (PDE4) inhibitors mimic the pharmacological actions of alpha2‐adrenoceptor antagonists. This has been postulated as the mechanism by which PDE4 inhibitors induce emesis and was also demonstrated by their ability to reverse xylazine/ketamine‐induced anaesthesia. We further characterized this latter effect since it appears to reflect the emetic potential of PDE4 inhibitors. Selective inhibitors of PDE 1, 2, 3, 4 and 5 were studied in rats, on the duration of anaesthesia… Expand
Inhibition of cAMP-phosphodiesterase 4 (PDE4) potentiates the anesthetic effects of Isoflurane in mice.
TLDR
It is shown that inhibition of cAMP-phosphodiesterase 4 (PDE4), while not inducing anesthesia by itself, potently enhances the anesthetic effects of Isoflurane in mice, and that pretreatment with a PDE4 inhibitor boosts the delivery of bacteria into the lungs of mice after intranasal infection under IsoFlurane. Expand
Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
TLDR
There is still a long way to go before PDE4 inhibitors with high therapeutic indices are available for treatment of depressive disorders, but important advances have been made in the development of Pde4 inhibitors as antidepressants. Expand
Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System
TLDR
The present data suggests that inhibitors targeting specific subtypes of PDE4 may exhibit differential pharmacological effects and aid a more efficient pharmacotherapy towards neuropsychological conditions. Expand
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
TLDR
Findings strongly support the hypothesis that inhibition of PDE4D is pivotal to the anesthesia-reversing effect of PMNPQ and is likely responsible for emesis induced by PDE 4 inhibitors. Expand
The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses
TLDR
It was found that combining sub-efficacious doses of the approved cognition-enhancer donepezil and roflumilast, which did not improve memory when given alone, fully restored object recognition memory deficit in rats induced by the muscarinic receptor antagonist scopolamine. Expand
Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
TLDR
ASP3258's potent inhibition of antigen-induced bronchoconstriction and airway hyperresponsiveness, two characteristic symptoms of bronchial asthma, suggests that this compound will be useful in treating asthma. Expand
Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia.
TLDR
Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect, and the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, because of the low therapeutic (PDE4(H)/PDE 4(L)) ratio. Expand
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
TLDR
Although ASP3258 inhibited airway inflammation completely, it had no emetic activity, and may be useful in treating airway inflammatory diseases such as asthma and COPD. Expand
Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
TLDR
Results suggest that inhibition of PDE-4 ameliorates HT-induced impairment of learning and memory functions. Expand
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice
TLDR
An allosteric inhibitor of PDE4D, which binds to a primate-specific, N-terminal region, was 100-fold more potent for improving memory than in wild-type mice and exhibited low potency in a mouse surrogate model for emesis, and clinical potential for PDE 4D-selective inhibitors is suggested. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
TLDR
The studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compounds trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacological actions of a pre-synaptic alpha(2)-adrenoceptor inhibition. Expand
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
TLDR
The results suggest that the PDE IV inhibitors studied are mixed peripheral-central emetogens, and whether emesis is mediated via a specific isoform of PDEIV remains to be established. Expand
Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat.
TLDR
Biochemical studies showed that rolipram induces various modifications in the turnover of monoamines but the net effect of these modifications on the electrical activity of monoaminergic neurons remained to be elucidated, which contrasts with that of most classical and new AD in which the Electrical activity of LC and/or DR neurons decreases. Expand
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐α and leukotriene B4 in a novel human whole blood assay
TLDR
stimulation of human whole blood with two LPS stimulations followed by fMLP gives rise to both TNF‐α and LTB4 and their inhibition by various compounds can be assessed in the same blood sample, confirming the anti‐inflammatory properties of PDE4 inhibitors. Expand
Emetic, central nervous system, and pulmonary activities of rolipram in the dog.
TLDR
Rolipram's reversal of anesthesia was confirmed in uninstrumented dogs, where rolipram shortened pentobarbital sleep time while increasing heart and respiratory rates and bronchodilatory selectivity after intragastrically administered i.v. administration. Expand
Pharmacokinetically Governed Design of Animal Toxicity Studies of a New Antidepressant Drug
TLDR
Rolipram (4-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-pyrrolidone) is a novel cAMP-phosphodiesterase inhibitor under clinical investigation as a low dose antidepressant drug and frequent vomiting is the main finding after all tested dosages. Expand
Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat.
TLDR
It is determined that the transduction mechanism for the hypnotic response to dexmedetomidine, a highly selective alpha 2 agonist, resides in the locus coeruleus (LC) of the rat, and candidates for the effector mechanism include inhibition of adenylate cyclase and cAMP-specific phosphodiesterase inhibitor. Expand
Conformational difference between PDE4 apoenzyme and holoenzyme.
TLDR
It is demonstrated that cofactor binding to PDE4 is responsible for eliciting its high-affinity interaction with cAMP and the activation of catalysis. Expand
Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system.
  • E. Macdonald, M. Scheinin
  • Biology, Medicine
  • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • 1995
TLDR
By examining the distribution of the mRNA coding for the three subtypes of the alpha 2-adrenoceptor, it has been possible to map those regions in the brain which possess cells which synthetize the distinct subtypes. Expand
Prevention of chronic cerebral vasospasm in dogs with milrinone.
TLDR
Mrinone is effective in preventing chronic cerebral vasospasm in a canine model of experimental chronic cerebral Vasospasm, and this effect is independent of changes in systemic hemodynamics. Expand
...
1
2
3
4
...